BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

3:58 PM
 | 
Sep 21, 2012
 |  BC Extra  |  Clinical News

MorphoSys gains on first RA efficacy data for MOR103

MorphoSys AG (Xetra:MOR; Pink:MPSYF) jumped EUR 2.92 (15%) to EUR 22.30 on Friday after reporting response data late Thursday from a Phase Ib/IIa trial evaluating four weekly doses of IV MOR103 to treat rheumatoid arthritis. Mid-dose MOR103...

Read the full 174 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >